Curt Labelle is a seasoned professional with over two decades of experience in the biotech and medtech sectors, currently serving as a member of the Board of Directors at Atticus Medical. His extensive background, which includes a joint MD and MBA from Columbia University, equips...
Curt Labelle is a seasoned professional with over two decades of experience in the biotech and medtech sectors, currently serving as a member of the Board of Directors at Atticus Medical. His extensive background, which includes a joint MD and MBA from Columbia University, equips him with a unique blend of clinical insight and business acumen. At Atticus Medical, Curt is instrumental in guiding the strategic direction of the company, particularly in the development of innovative therapies aimed at addressing significant health challenges, such as River Blindness. His involvement in this project underscores his commitment to impact investing and the advancement of healthcare solutions that can transform patient outcomes.
Curt's expertise in venture financing and growth capital has been pivotal in securing funding for groundbreaking initiatives within the pharmaceutical and biotechnology landscapes. His previous roles on the boards of successful companies like Sirion Therapeutics and Eyenovia have honed his ability to identify and nurture high-potential investments. Notably, his leadership in the sale of a Priority Review Voucher for moxidectin demonstrates his strategic foresight and understanding of regulatory pathways, which can accelerate the development and commercialization of critical therapies.
With a keen focus on ophthalmology, Curt leverages his skills to foster collaborations that drive innovation and enhance the delivery of healthcare solutions. His passion for advancing medical technology and improving patient care continues to guide his contributions at Atticus Medical, where he plays a vital role in shaping the future of therapeutic development in the industry.
